Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Lexicon Pharmaceuticals

DB:LX31
Snowflake Description

Undervalued with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LX31
DB
$187M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
  • Lexicon Pharmaceuticals has significant price volatility in the past 3 months.
LX31 Share Price and Events
7 Day Returns
-11.7%
DB:LX31
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-71.4%
DB:LX31
-7.4%
DE Biotechs
-14.2%
DE Market
LX31 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lexicon Pharmaceuticals (LX31) -11.7% -19.9% -55.5% -71.4% -88.5% -75.4%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • LX31 underperformed the Biotechs industry which returned -7.4% over the past year.
  • LX31 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
LX31
Industry
5yr Volatility vs Market

LX31 Value

 Is Lexicon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Lexicon Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Lexicon Pharmaceuticals.

DB:LX31 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:LX31
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (131.86%))
1.764
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.76
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.764 * 5.44%)
9.2%

Discounted Cash Flow Calculation for DB:LX31 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Lexicon Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:LX31 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.2%)
2020 -224.00 Analyst x1 -205.12
2021 125.00 Analyst x1 104.82
2022 152.48 Est @ 21.99% 117.09
2023 175.78 Est @ 15.27% 123.59
2024 194.37 Est @ 10.58% 125.14
2025 208.53 Est @ 7.29% 122.95
2026 218.92 Est @ 4.98% 118.19
2027 226.30 Est @ 3.37% 111.88
2028 231.37 Est @ 2.24% 104.75
2029 234.73 Est @ 1.45% 97.31
Present value of next 10 years cash flows $820.00
DB:LX31 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $234.73 × (1 + -0.39%) ÷ (9.2% – -0.39%)
$2,436.95
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,436.95 ÷ (1 + 9.2%)10
$1,010.26
DB:LX31 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $820.00 + $1,010.26
$1,830.26
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,830.26 / 106.97
$17.11
DB:LX31 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:LX31 represents 0.87088x of NasdaqGS:LXRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87088x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 17.11 x 0.87088
€14.90
Value per share (EUR) From above. €14.90
Current discount Discount to share price of €1.59
= -1 x (€1.59 - €14.90) / €14.90
89.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Lexicon Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €1.59 vs Future cash flow value of €14.9
Current Discount Checks
For Lexicon Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Lexicon Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Lexicon Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lexicon Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lexicon Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LX31 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $1.23
NasdaqGS:LXRX Share Price ** NasdaqGS (2020-04-08) in USD $1.82
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lexicon Pharmaceuticals.

DB:LX31 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:LXRX Share Price ÷ EPS (both in USD)

= 1.82 ÷ 1.23

1.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexicon Pharmaceuticals is good value based on earnings compared to the Europe Biotechs industry average.
  • Lexicon Pharmaceuticals is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Lexicon Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:LX31 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 1.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-8.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:LX31 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 1.49x ÷ -8.7%

-0.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexicon Pharmaceuticals earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lexicon Pharmaceuticals's assets?
Raw Data
DB:LX31 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.10
NasdaqGS:LXRX Share Price * NasdaqGS (2020-04-08) in USD $1.82
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:LX31 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:LXRX Share Price ÷ Book Value per Share (both in USD)

= 1.82 ÷ 1.10

1.65x

* Primary Listing of Lexicon Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lexicon Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Lexicon Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Lexicon Pharmaceuticals has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LX31 Future Performance

 How is Lexicon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lexicon Pharmaceuticals expected to grow at an attractive rate?
  • Lexicon Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Lexicon Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Lexicon Pharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LX31 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LX31 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -8.7%
DB:LX31 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts -10%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LX31 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LX31 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 192 -12 3
2023-12-31 162 -18 3
2022-12-31 112 -69 4
2021-12-31 124 -89 -56 4
2020-12-31 38 -175 -242 4
2020-04-08
DB:LX31 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 322 114 130
2019-09-30 330 111 164
2019-06-30 43 -102 -89
2019-03-31 47 -127 -101
2018-12-31 63 -149 -121
2018-09-30 81 -155 -126
2018-06-30 101 -167 -129
2018-03-31 99 -147 -130
2017-12-31 92 -185 -123
2017-09-30 80 -200 -133
2017-06-30 81 -202 -138
2017-03-31 89 -217 -141

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lexicon Pharmaceuticals's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Lexicon Pharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LX31 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LX31 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.20 0.89 -1.28 2.00
2023-12-31 -0.21 0.54 -0.95 2.00
2022-12-31 -0.48 0.10 -1.02 3.00
2021-12-31 -0.21 0.58 -1.25 4.00
2020-12-31 -2.22 -2.12 -2.31 4.00
2020-04-08
DB:LX31 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 1.23
2019-09-30 1.55
2019-06-30 -0.84
2019-03-31 -0.95
2018-12-31 -1.14
2018-09-30 -1.19
2018-06-30 -1.22
2018-03-31 -1.23
2017-12-31 -1.17
2017-09-30 -1.27
2017-06-30 -1.33
2017-03-31 -1.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lexicon Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Lexicon Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lexicon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LX31 Past Performance

  How has Lexicon Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lexicon Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lexicon Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
  • Lexicon Pharmaceuticals has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Lexicon Pharmaceuticals has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Lexicon Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LX31 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 322.07 130.13 56.84
2019-09-30 330.42 164.49 58.83
2019-06-30 42.94 -88.99 60.52
2019-03-31 47.05 -100.53 63.01
2018-12-31 63.21 -120.55 63.75
2018-09-30 80.54 -126.09 63.21
2018-06-30 100.52 -129.41 64.36
2018-03-31 98.77 -129.92 66.08
2017-12-31 91.69 -122.99 66.09
2017-09-30 80.33 -133.09 64.04
2017-06-30 81.10 -138.38 59.58
2017-03-31 89.14 -141.44 49.52
2016-12-31 79.26 -131.45 43.16
2016-09-30 187.58 -22.26 35.53
2016-06-30 160.43 -21.53 28.64
2016-03-31 140.72 -11.49 26.53
2015-12-31 130.01 -4.68 23.84
2015-09-30 24.22 -94.37 21.38
2015-06-30 24.07 -99.58 20.61
2015-03-31 24.37 -97.54 19.46
2014-12-31 22.85 -100.29 19.41
2014-09-30 2.78 -114.78 18.84
2014-06-30 2.60 -105.94 18.93
2014-03-31 2.14 -108.99 18.45
2013-12-31 2.22 -104.13 17.12
2013-09-30 1.03 -111.59 17.63
2013-06-30 1.16 -109.47 17.31

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Whilst Lexicon Pharmaceuticals made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%), this is metric is skewed due to its high level of debt.
  • Lexicon Pharmaceuticals used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Lexicon Pharmaceuticals has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess Lexicon Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lexicon Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LX31 Health

 How is Lexicon Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lexicon Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lexicon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lexicon Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lexicon Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lexicon Pharmaceuticals Company Filings, last reported 3 months ago.

DB:LX31 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 117.10 245.18 271.66
2019-09-30 164.71 245.13 296.30
2019-06-30 -64.89 245.07 105.98
2019-03-31 -45.69 245.03 133.15
2018-12-31 -26.41 245.00 160.05
2018-09-30 -29.40 244.95 187.30
2018-06-30 -5.07 245.09 209.69
2018-03-31 26.19 245.40 262.27
2017-12-31 68.27 245.67 310.79
2017-09-30 78.38 100.15 196.82
2017-06-30 106.31 100.54 231.19
2017-03-31 134.60 101.02 259.74
2016-12-31 157.40 101.45 346.50
2016-09-30 185.18 101.83 395.56
2016-06-30 217.33 102.20 429.37
2016-03-31 252.88 102.57 477.15
2015-12-31 285.85 102.94 521.35
2015-09-30 197.94 106.29 255.99
2015-06-30 231.47 106.76 282.05
2015-03-31 257.61 107.21 314.67
2014-12-31 284.02 107.67 338.91
2014-09-30 77.82 20.61 57.44
2014-06-30 116.67 21.04 78.61
2014-03-31 140.78 21.46 97.94
2013-12-31 170.16 21.88 129.13
2013-09-30 185.71 22.28 150.78
2013-06-30 215.08 22.68 174.95
  • Lexicon Pharmaceuticals's level of debt (209.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (37.9% vs 209.4% today).
  • Debt is well covered by operating cash flow (46.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 9.8x coverage).
X
Financial health checks
We assess Lexicon Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lexicon Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LX31 Dividends

 What is Lexicon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lexicon Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Lexicon Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lexicon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lexicon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LX31 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LX31 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lexicon Pharmaceuticals has not reported any payouts.
  • Unable to verify if Lexicon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lexicon Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lexicon Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Lexicon Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Lexicon Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lexicon Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lexicon Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LX31 Management

 What is the CEO of Lexicon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Lonnel Coats
COMPENSATION $3,870,291
AGE 54
TENURE AS CEO 5.8 years
CEO Bio

Mr. Lonnel Coats has been the Chief Executive Officer and President of Lexicon Pharmaceuticals, Inc., since July 7, 2014. Mr. Coats served as an Executive Vice President, President of Americas Region at Eisai Inc. He served as the Chief Executive Officer of Eisai Inc from June 18, 2010 to April 1, 2014 and President of Eisai Inc from 2004 to April 1, 2014 and served as its Vice President and Senior Vice President. He was Executive Officer at Eisai Inc from April 1, 2014 to June 2014. He served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., from 1996 to June 2014. Mr. Coats also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats served as Chief Executive Officer and President of Eisai, Inc. until April 1, 2014. He served as Chief Operating Officer at Eisai Corporation of North America, Inc until June 2010 and President. He served as Executive Vice President at Eisai Co., Ltd. and its Senior Vice President since June 2010. He served as Vice President at Eisai Co., Ltd. until June 2010. He served as the Chief Operating Officer of Eisai Inc from 2004 to June 18, 2010. Mr. Coats has been a Director of Blueprint Medicines Corporation since February 4, 2016 and Lexicon Pharmaceuticals, Inc. since July 2014. Mr. Coats served as a Director of MGI Pharma, Inc. since January 2008. He serves as Member of Board of Governors at Hackensack University Medical Center. He holds a B.S. in Public Administration from Oakland University in Michigan. Eisai

CEO Compensation
  • Lonnel's compensation has increased in line with Lexicon Pharmaceuticals recently becoming profitable.
  • Lonnel's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Lexicon Pharmaceuticals management team in years:

7.8
Average Tenure
59
Average Age
  • The average tenure for the Lexicon Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Lonnel Coats

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
5.8 yrs

Jeffrey Wade

TITLE
Executive VP of Corporate & Administrative Affairs and CFO
COMPENSATION
$2M
AGE
54
TENURE
9.9 yrs

Alan Main

TITLE
Executive Vice President of Commercial Supply Operations
COMPENSATION
$85K
AGE
65
TENURE
18.8 yrs

Pablo Lapuerta

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$1M
AGE
56
TENURE
5.2 yrs

Praveen Tyle

TITLE
Executive Vice President of Research & Development
COMPENSATION
$2M
AGE
59
TENURE
3.9 yrs

Alex Santini

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$1M
AGE
60
TENURE
3.4 yrs

Robert Lefkowitz

TITLE
Consultant & Independent Director
COMPENSATION
$89K
AGE
75
TENURE
17.1 yrs

James Tessmer

TITLE
Vice President of Finance & Accounting
COMPENSATION
$508K
AGE
59
TENURE
12.4 yrs

Kimberly Lee

TITLE
Head of Investor Relations & Corporate Strategy

Brian Crum

TITLE
VP, General Counsel & Secretary
AGE
46
Board of Directors Tenure

Average tenure and age of the Lexicon Pharmaceuticals board of directors in years:

12.7
Average Tenure
64
Average Age
  • The average tenure for the Lexicon Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ray Debbane

TITLE
Independent Chairman of the Board
COMPENSATION
$118K
AGE
64
TENURE
8.2 yrs

Lonnel Coats

TITLE
President
COMPENSATION
$4M
AGE
54
TENURE
5.8 yrs

Sam Barker

TITLE
Independent Director
COMPENSATION
$107K
AGE
76
TENURE
20.1 yrs

Robert Lefkowitz

TITLE
Consultant & Independent Director
COMPENSATION
$89K
AGE
75
TENURE
19.2 yrs

Alan Nies

TITLE
Chairman of Medical Advisory Board & Independent Director
COMPENSATION
$137K
AGE
81
TENURE
17.1 yrs

Frank Palantoni

TITLE
Independent Director
COMPENSATION
$106K
AGE
62
TENURE
15.4 yrs

Philippe Amouyal

TITLE
Independent Director
COMPENSATION
$91K
AGE
60
TENURE
12.7 yrs

Christopher Sobecki

TITLE
Independent Director
COMPENSATION
$85K
AGE
60
TENURE
12.7 yrs

Judith Swain

TITLE
Independent Director
COMPENSATION
$97K
AGE
70
TENURE
12.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
19. Sep 19 Buy Lonnel Coats Individual 18. Sep 19 18. Sep 19 50,000 €2.80 €140,105
19. Sep 19 Buy Alexander Santini Individual 18. Sep 19 18. Sep 19 4,500 €3.18 €13,662
18. Sep 19 Buy Lonnel Coats Individual 17. Sep 19 17. Sep 19 50,000 €2.83 €141,467
17. Sep 19 Buy Raymond Debbane Individual 13. Sep 19 16. Sep 19 300,515 €2.55 €684,113
17. Sep 19 Buy Christopher Sobecki Individual 13. Sep 19 16. Sep 19 124,249 €2.50 €275,034
20. Aug 19 Buy Lonnel Coats Individual 16. Aug 19 19. Aug 19 40,000 €1.26 €48,701
02. Aug 19 Buy James Tessmer Individual 02. Aug 19 02. Aug 19 10,000 €1.03 €10,263
02. Aug 19 Buy Samuel Barker Individual 02. Aug 19 02. Aug 19 24,000 €1.06 €25,388
X
Management checks
We assess Lexicon Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lexicon Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LX31 News

Simply Wall St News

LX31 Company Info

Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase III clinical trials for the treatment of type 1 and type 2 diabetes; LX9211, which is in Phase Ib clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Details
Name: Lexicon Pharmaceuticals, Inc.
LX31
Exchange: DB
Founded: 1995
$171,884,700
106,969,973
Website: http://www.lexpharma.com
Address: Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place,
The Woodlands,
Texas, 77381,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS LXRX Common Shares Nasdaq Global Select US USD 07. Apr 2000
DB LX31 Common Shares Deutsche Boerse AG DE EUR 07. Apr 2000
MUN LX31 Common Shares Boerse Muenchen DE EUR 07. Apr 2000
Number of employees
Current staff
Staff numbers
184
Lexicon Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:26
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.